Persephoni Backs SelSym Biotech to Bring Blood-Type-Agnostic Bleeding Control to the Point of Injury

SelSym Biotech joins Persephoni to advance the first shelf-stable, blood-type agnostic hemostatic therapy designed for use at the point of injury, where no such option exists today RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) — Persephoni BioSciences (“Persephoni”), a global venture creation platform, today announced that SelSym Biotech (“SelSym”), a preclinical-stage company developing […]